Thursday, February 22, 2007

A couple of extra thoughts from 2006

-Anybody else surprised that Iressa racked up nearly a quarter billion in revenue? I thought AZ was just maintaining Iressa in the hopes that biomarker/personalized medicine research would fully characterize responders with significant sales to come only after conclusive studies, but Iressa is still achieving good levels of revenue.

-it's early, but it doesn't look like Vectibix negatively affected Erbitux.

-For an eight year old drug, Herceptin's nearly half-billion dollar revenue gain is very impressive. (Uh, actually, a half-billion dollar revenue gain is great for anyone, anytime.)

-Earning honors as "First KD to drop off the list," Macugen probably will come very close to zeroing out in 2007, as OSI is exiting the business, as detailed today....

-.....because of Lucentis, which had an amazing introduction in 2006.

2 comments:

TotallyMedicinal said...

If you consider the initial sales projections for Glivec (?? ~250m USD pa??) and actual sales (?? >2bn USD pa) perhaps the success of Iressa isn't all that surprising.

Maybe oncologists out there are giving it a shot off-label in poor prognosis cases, in combination with other medications? I am not at all clued up on the side-effect profile, but if it's not too bad, the oncologists may be thinking, Can it do any harm to give it a shot?

Anonymous said...

Welcome to our website for you World of Warcraft Gold,Wow Gold,Cheap World of Warcraft Gold,cheap wow gold,buy cheap wow gold,real wow gold,sell wow gold, ...
Here wow gold of 1000 gold at $68.99-$80.99 ,World Of Warcraft Gold,buy wow gold,sell world of warcraft gold(wow gold),buy euro gold wow Cheap wow gold,cheapest wow gold store ... buy euro gold wow wow gold--buy cheap wow gold,sell wow gold.welcome to buy cheap wow gold--cheap, easy, wow gold purchasing.World of Warcraft,wow gold Super ...